“We are excited to see that Transpara features in both the clinical and medical education programs this year and look forward to hearing the results on earlier breast cancer detection,”
BUDAPEST, Hungary (PRWEB) October 03, 2019
EUSOBI Booth #2 – Transpara™ by ScreenPoint Medical to showcase new medical education program to demonstrate real life use of breast AI.
At EUSOBI in Budapest, ScreenPoint Medical will launch its new medical education program with a series of workshops entitled, “The Transpara experience – true multi-vendor, evidence-based breast AI for mammography.”
Transpara is an AI solution for breast cancer screening, that uses deep learning algorithms to automatically detect lesions suspicious for breast cancer in 2D and 3D mammograms. The software categorises mammograms on a 10-point scale indicating the risk that cancer is present. This Exam Score can be used to triage examinations and help radiologists to prioritise patients for further investigation. Interactive decision support of suspicious regions is provided to support radiologists with image interpretation. Studies have shown that Transpara matches the performance of radiologists , thus acting as a second opinion which increases diagnostic confidence and accuracy .
"The launch of our medical education program at EUSOBI shows our strong commitment to training in the use of commercially available breast AI," said Nico Karssemeijer, CEO for ScreenPoint Medical. "Customers are looking for evidence-based AI solutions that work with their current IT and mammography infrastructure, so we worked hard to develop these masterclass hands-on workshops to demonstrate what Transpara can do right now for radiologists in their daily clinical practice."
In parallel to these dedicated Transpara activities, ScreenPoint Medical is partnering with Siemens Healthineers for the “mammography reading beyond scrolling through the slices” workshops.
“The EUSOBI meeting is an important highlight in the breast imaging calendar. We are excited to see that Transpara features in both the clinical and medical education programs this year and look forward to hearing the results on earlier breast cancer detection,” adds ScreenPoint Medical co-founder Sir Michael Brady.
These commercially available 2D, 3D and combo mammography solutions are on display at the Annual European Society of Breast Imaging (EUSOBI) meeting in Budapest, Hungary this week.
About ScreenPoint Medical:
ScreenPoint Medical is a leader in the development of image analysis technology which enables the automated reading of mammograms and digital breast tomosynthesis examinations. With proven accuracy matching that of experienced radiologists, ScreenPoint’s Transpara™ system is the most advanced available, exploiting Big Data, Deep Learning and the latest advances in Artificial Intelligence. The system can identify high risk breast lesions faster than before enabling earlier detection, earlier treatment and a greater chance of survival.
ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Sir Michael Brady, two internationally respected experts in breast imaging, machine learning and computer aided detection.
The company’s Head Office is in Nijmegen, The Netherlands. For more information, please email firstname.lastname@example.org.